Internet of things-based lifestyle intervention for prostate cancer patients on androgen deprivation therapy : a prospective, multicenter, randomized trial
AJCR Copyright © 2021..
Androgen deprivation therapy (ADT) has several adverse effects including loss of libido, osteoporosis, and metabolic complications. We aim to examine whether the Smart After-Care (SAC) service, an Internet of Things (IoT)-based lifestyle intervention, affects clinical outcomes in prostate cancer (PCa) patients on ADT. A prospective, multicenter, randomized trial including 172 patients randomly assigned to the SAC or control group was conducted. The SAC group was provided with a smartphone application providing a personalized exercise program, daily activity monitoring, and diet counselling. The control group was briefly educated on the exercise program using a paper brochure. The primary endpoint was increase in cardiorespiratory endurance assessed using the 2-minute walking test (2MWT). Secondary endpoints included improved muscle strength (hand grip strength test and 30-second chair stand test), short physical performance battery, body composition, and health-related quality of life (EORTC-QLQ-C30 and PR25). Participants in both groups showed significant improvement in the 2MWT and 30-second chair stand test after 12 weeks of intervention. Greater improvement in the 2MWT was observed in the SAC group than in the control group. Significantly increased body fat ratio was observed in both groups; however, decreased skeletal muscle mass was observed only in the control group. Marginal improvement in skeletal muscle mass was observed over time in the SAC group when compared with that in the control group. Both groups showed improvement in all physical scales in the EORTC-QLQ-C30 questionnaire, and the SAC group showed a significant interaction of group and time for social functioning scales. SAC improved cardiorespiratory endurance, sarcopenic obesity, and health-related quality of life in patients with PCa on ADT.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
American journal of cancer research - 11(2021), 11 vom: 02., Seite 5496-5507 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Park, Yong Hyun [VerfasserIn] |
|---|
| Themen: |
Androgen deprivation therapy |
|---|
| Anmerkungen: |
Date Revised 08.12.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM334101549 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334101549 | ||
| 003 | DE-627 | ||
| 005 | 20231225223014.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334101549 | ||
| 035 | |a (NLM)34873475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Park, Yong Hyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Internet of things-based lifestyle intervention for prostate cancer patients on androgen deprivation therapy |b a prospective, multicenter, randomized trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 08.12.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJCR Copyright © 2021. | ||
| 520 | |a Androgen deprivation therapy (ADT) has several adverse effects including loss of libido, osteoporosis, and metabolic complications. We aim to examine whether the Smart After-Care (SAC) service, an Internet of Things (IoT)-based lifestyle intervention, affects clinical outcomes in prostate cancer (PCa) patients on ADT. A prospective, multicenter, randomized trial including 172 patients randomly assigned to the SAC or control group was conducted. The SAC group was provided with a smartphone application providing a personalized exercise program, daily activity monitoring, and diet counselling. The control group was briefly educated on the exercise program using a paper brochure. The primary endpoint was increase in cardiorespiratory endurance assessed using the 2-minute walking test (2MWT). Secondary endpoints included improved muscle strength (hand grip strength test and 30-second chair stand test), short physical performance battery, body composition, and health-related quality of life (EORTC-QLQ-C30 and PR25). Participants in both groups showed significant improvement in the 2MWT and 30-second chair stand test after 12 weeks of intervention. Greater improvement in the 2MWT was observed in the SAC group than in the control group. Significantly increased body fat ratio was observed in both groups; however, decreased skeletal muscle mass was observed only in the control group. Marginal improvement in skeletal muscle mass was observed over time in the SAC group when compared with that in the control group. Both groups showed improvement in all physical scales in the EORTC-QLQ-C30 questionnaire, and the SAC group showed a significant interaction of group and time for social functioning scales. SAC improved cardiorespiratory endurance, sarcopenic obesity, and health-related quality of life in patients with PCa on ADT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a androgen deprivation therapy | |
| 650 | 4 | |a internet of things | |
| 650 | 4 | |a lifestyle intervention | |
| 650 | 4 | |a randomized trial | |
| 650 | 4 | |a smart after-care | |
| 700 | 1 | |a Lee, Jong In |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ji Youl |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, In Yae |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Ji Hye |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Seong Il |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kang Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoo, Ji Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Seung Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a So, Yekyeong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of cancer research |d 2011 |g 11(2021), 11 vom: 02., Seite 5496-5507 |w (DE-627)NLM207988722 |x 2156-6976 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:11 |g day:02 |g pages:5496-5507 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 11 |b 02 |h 5496-5507 | ||